AMBS Stock | News | Quote | Stock Forum | Friday, December 27,

New Post Public Reply Private Reply Replies (0) Message Board

Dec 27, 2013 at 1:51 AM

$AMBS Amarantus Bioscience Holdings, Inc. AMBS Company Overview

Amarantus Bioscience Holdings, Inc. AMBS Current Price and Quotes
Last Price 0.0666
Previous Close 0.054 Open 0.0549
Daily Range 0.0675 - 0.0545 52wk Range 0.195 - 0.027
Volume 10,599,173 Dividend N/A
Average Vol (3m) 3,489,000 Yield N/A

AMBS Stock Message Board http://investorshangout.com/search?q=AMBS&...mp;yt1=Go!

Last Updated: Friday, December 27, 2013 01:51:28 AM

Amarantus Bioscience Holdings, Inc. AMBS
Company Information

675 Almanor Ave
Sunnyvale, CA

Website: http://www.amarantus.com
Phone: 408-737-2734
Email: gerald@amarantus.com
Find us on:

Amarantus Bioscience Holdings, Inc. AMBS
Amarantus BioScience, Inc. is a development-stage biotechnology company founded in January 2008. The Company is focused on developing unique products and proprietary technologies for the potential treatment and/or diagnosis of Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, Ischemic Heart Disease and other human diseases. The Company owns the intellectual property rights to Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as tr...

Amarantus Bioscience Holdings, Inc. AMBS
Financial Reportings and Disclosures

Reporting Status U.S. Reporting: SEC Filer
Audited Financials Audited
Latest Report Sep 30, 2013 10-Q
CIK 0001424812
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data

SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Nov 19, 2012
Incorporated In: NV, USA
Year of Inc. 2008
Employees 3 a/o Nov 19, 2012
Company Officers/Contacts

Gerald E. Commissiong CEO, President, COO
Marc E. Faerber CFO, Treasurer, Secretary
John W. Commissiong CSO
Company Directors

Mark Benedyk
Gerald E. Commissiong
John W. Commissiong
Robert L. Harris
David A. Lowe
Company Notes

Formerly=Amarantus Bioscience, Inc. until 4-2013
Formerly=Amarantus Biosciences, Inc. until 12-2012
Formerly=Jumpkicks, Inc. until 6-2011
Service Providers

Auditor/Accountant
Silberstein Ungar, PLLC
30600 Telegraph Rd.
Suite 2175
Bingham Farms, MI, 48025
United States

Legal Counsel
Sichenzia Ross Friedman Ference LLP
61 Broadway
New York, NY, 10006
United States

Investor Relations Firm
LHA Inc.
800 Third Ave.
New York, NY, 10022
United States

Amarantus Bioscience Holdings, Inc. AMBS
AMBS Security Details

Share Structure

Market Value1 $29,777,965 a/o Dec 26, 2013
Shares Outstanding 551,443,794 a/o Nov 13, 2013
Float Not Available
Authorized Shares 1,000,000,000 a/o Nov 14, 2012
Par Value 0.001
Shareholders

Shareholders of Record 64 a/o Apr 26, 2013
Corporate Actions

Ex. Date Record Date Pay Date
Dividend (0.00) Jun 14, 2011 Jun 06, 2011 Jun 13, 2011
Security Notes

Capital Change=shs increased by 25 for 1 split. Ex-date=06/14/2011. Rec date=06/06/2011. Pay date=06/13/2011.
Short Selling Data

Short Interest 7,350 (-88.62%)
Dec 13, 2013
Significant Failures to Deliver No
Transfer Agent(s)

VStock Transfer

Amarantus Bioscience Holdings, Inc. AMBS Financials
Period Ending Dec 31, 2012 Dec 31, 2011 Dec 31, 2010 Oct 31, 2010
Total Revenue - 224 192 -
Cost of Revenue - - - -
Gross Profit - 224 192 -
Operating Expenses

Research and Development 584 1,178 490 -
Sales, General and Admin. 3,506 2,786 924 57
Non-Recurring Items - - - -
Other - - - 1
Operating Income (4,090) (3,740) (1,223) (59)
Income From Continuing Operations

Add'l Income/Expense Items 473 315 94 -
Earnings Before Interest and Tax (3,617) (3,425) (1,128) (59)
Interest Expense 1,518 1,015 79 -
Earnings Before Tax (5,136) (4,440) (1,208) (59)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (5,136) (4,440) (1,208) (59)
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (5,136) (4,440) (1,208) (59)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (5,136) (4,440) (1,208) (59)

Amarantus Bioscience Holdings, Inc. AMBS Recent News

Dec 18, 2013 Amarantus Licenses MANF-Related Wolfram's and Diabetes Therapeutic and Diagnostic Intellectual Property From University of Massachusetts Medical School
Dec 17, 2013 Amarantus and Brewer Sports Announce ONE MIND for Research at 2nd #C4CT Concussion Awareness Summit Prior to Super Bowl XLVIII at United Nations
Dec 3, 2013 Amarantus Obtains Exclusive Option to License University of Miami Bascom Palmer Eye Institute's Intellectual Property for the Treatment of Retinal Diseases Using MANF and CDNF
Nov 26, 2013 Amarantus BioScience to Present at the LD Micro Sixth Annual Conference on December 3, 2013
Nov 14, 2013 Amarantus Reports Third Quarter 2013 Financial Results and Development Progress
Nov 14, 2013 Exclusive Insight on ITEN, MSLP and AMBS
Nov 13, 2013 Amarantus and Brewer Sports Announce 2nd #C4CT Concussion Awareness Summit Surrounding Super Bowl XLVIII
Nov 12, 2013 Amarantus BioScience CSO Publishes New Blog Entitled "The Golden Goose: Preparing PhenoGuard to Lay the Next Golden Egg"
Nov 8, 2013 Stocks Under Review - WTER, BRGO, AMBS and TDEY
Nov 6, 2013 Amarantus Appoints David A. Lowe, PhD to Board of Directors

1
2
next >

AMBS Amarantus Bioscience Holdings, Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=AMBS&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/AMBS/quote
Stock Chart http://www.otcmarkets.com/stock/AMBS/chart
Company Info http://www.otcmarkets.com/stock/AMBS/company-info
Recent News http://www.otcmarkets.com/stock/AMBS/news
Financials http://www.otcmarkets.com/stock/AMBS/financials
Filings and Disclosure http://www.otcmarkets.com/stock/AMBS/filings
Short Sales http://www.otcmarkets.com/stock/AMBS/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/AMBS/insider-transactions
Research Reports http://www.otcmarkets.com/stock/AMBS/research
Summary http://finance.yahoo.com/q?s=AMBS
Historical Prices http://finance.yahoo.com/q/hp?s=AMBS+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=AMBS
Basic Chart http://finance.yahoo.com/q/bc?s=AMBS+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=AMBS+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=AMBS+Headlines
Press Releases http://finance.yahoo.com/q/p?s=AMBS+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=AMBS+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=AMBS+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=AMBS+Industry
Major Holders http://finance.yahoo.com/q/mh?s=AMBS+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=AMBS+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=AMBS+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=AMBS
Balance Sheet http://finance.yahoo.com/q/bs?s=AMBS
Cash Flow http://finance.yahoo.com/q/cf?s=AMBS+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/AMBS
Market Watch http://www.marketwatch.com/investing/stock/AMBS
Bloomberg http://www.bloomberg.com/quote/AMBS:US
Morningstar http://quotes.morningstar.com/stock/s?t=AMBS
Bussinessweek http://investing.businessweek.com/research/st...icker=AMBS
Barchart http://www.barchart.com/quotes/stocks/AMBS
OTC Short Report http://otcshortreport.com/index.php?index=AMBS
Investopedia http://www.investopedia.com/markets/stocks/AMBS/?wa=0

List of all stock message boards and tickers for OTC BB Pinks & Penny Stocks http://investorshangout.com/board?categoryid=OTC

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

TCL's Display Future: AI Meets Screens at DTC 2026

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Amplifon Data Breach Spurs Legal Scrutiny for Millions

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...